Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1873 Target Snapshot

Tissue-type plasminogen activator · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,434Compounds
244Assays
2Approved Drugs
1,267.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Tissue-type plasminogen activator shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P00750. Start with myocardial infarction, then reuse UniProt P00750 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with myocardial infarction, then reuse UniProt P00750 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
myocardial infarction

Tissue-type plasminogen activator shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with myocardial infarction because it currently carries approved-linked support. Linked drugs include ALTEPLASE, RETEPLASE, TENECTEPLASE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tissue-type plasminogen activator as ChEMBL target CHEMBL1873, mapped to UniProt P00750. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tissue-type plasminogen activator
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1873
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P00750
Tissue-type plasminogen activator
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tissue-type plasminogen activator is the right protein anchor across sources, using UniProt P00750 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why myocardial infarction is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTissue-type plasminogen activator
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP00750
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTissue-type plasminogen activator
UniProt AccessionP00750
Component TypeProtein
Sequence Length562 aa

Tissue-type plasminogen activator

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Tissue-type plasminogen activator, mapped to UniProt P00750. Sequence length is 562 aa.

Mapped IDP00750
Review nameTissue-type plasminogen activator
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Tissue-type plasminogen activator shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
myocardial infarction
3 linked drugs · 3 direct · 3 efficacy
Linked drugALTEPLASE
Linked drugRETEPLASE
Linked drugTENECTEPLASE
Approved-linked Approved
Recurrent thrombophlebitis
3 linked drugs · 3 direct · 3 efficacy
Linked drugALTEPLASE
Linked drugRETEPLASE
Linked drugTENECTEPLASE
Approved-linked Approved
stroke
3 linked drugs · 3 direct · 3 efficacy
Linked drugALTEPLASE
Linked drugRETEPLASE
Linked drugTENECTEPLASE
Approved-linked Approved
heart failure
2 linked drugs · 2 direct · 2 efficacy
Linked drugALTEPLASE
Linked drugRETEPLASE
Approved-linked Approved
hemorrhage
2 linked drugs · 2 direct · 2 efficacy
Linked drugALTEPLASE
Linked drugAMINOCAPROIC ACID
Approved-linked Approved
pulmonary embolism
2 linked drugs · 2 direct · 2 efficacy
Linked drugALTEPLASE
Linked drugTENECTEPLASE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with myocardial infarction because it currently carries approved-linked support. Linked drugs include ALTEPLASE, RETEPLASE, TENECTEPLASE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemyocardial infarction
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
3
Phase III
2
Phase II
Assay Mix

Activity Type Distribution

IC50768.0
KI499.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL439678 9.54 Ki 0.29 Preclinical
CHEMBL105819 9.15 IC50 0.7 Preclinical
CHEMBL92615 8.52 Ki 3.0 Preclinical
CHEMBL290376 8.24 Ki 5.7 Preclinical
CHEMBL418965 8.22 Ki 6.0 Preclinical
CHEMBL5901486 8.22 IC50 6.0 Preclinical
CHEMBL94952 8.22 Ki 6.0 Preclinical
CHEMBL4457757 8.1 IC50 8.0 Preclinical
CHEMBL4460436 8.1 IC50 8.0 Preclinical
CHEMBL5964796 8.09 IC50 8.2 Preclinical
Distribution

pChEMBL Value Distribution

106
5.0
56
5.5
54
6.0
53
6.5
221
7.0
215
7.5
15
8.0
1
8.5
1
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

MELAGATRAN
CHEMBL266349
Approved 2004
Properties Compare Identifier
Assay Landscape

Assay Landscape

244
Total Assays
870
Tested Compounds
3
Assay Types
Binding — 239 assays, 870 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 237 411 5.4
assay format 1 459 7.5
cell-free format 1 0 —
Functional — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 0 —
ADME — 1 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 13 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine